AIM IMMUNOTECH INC (AIM)
US00901B1052 - Common Stock
Taking everything into account, AIM scores 3 out of 10 in our fundamental rating. AIM was compared to 588 industry peers in the Biotechnology industry. The financial health of AIM is average, but there are quite some concerns on its profitability. AIM is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
AIM had negative earnings in the past year.
In the past year AIM has reported a negative cash flow from operations.
In the past 5 years AIM always reported negative net income.
In the past 5 years AIM always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -149.44%, AIM is not doing good in the industry: 85.84% of the companies in the same industry are doing better.
The Return On Equity of AIM (-283.00%) is worse than 73.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -149.44% | ||
| ROE | -283% | ||
| ROIC | N/A |
ROA(3y)-76.87%
ROA(5y)-59.64%
ROE(3y)-122.39%
ROE(5y)-92.13%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AIM has a Gross Margin of 79.21%. This is amongst the best in the industry. AIM outperforms 87.54% of its industry peers.
The Profit Margin and Operating Margin are not available for AIM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.21% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
AIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
AIM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AIM has more shares outstanding
AIM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -33.32, we must say that AIM is in the distress zone and has some risk of bankruptcy.
AIM has a Altman-Z score of -33.32. This is amonst the worse of the industry: AIM underperforms 91.81% of its industry peers.
AIM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -33.32 |
ROIC/WACCN/A
WACC9.22%
2.3 Liquidity
A Current Ratio of 1.68 indicates that AIM should not have too much problems paying its short term obligations.
AIM's Current ratio of 1.68 is on the low side compared to the rest of the industry. AIM is outperformed by 79.35% of its industry peers.
AIM has a Quick Ratio of 1.68. This is a normal value and indicates that AIM is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of AIM (1.68) is worse than 78.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.68 | ||
| Quick Ratio | 1.68 |
3. Growth
3.1 Past
AIM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -50.00%.
AIM shows a strong growth in Revenue. In the last year, the Revenue has grown by 44.29%.
The Revenue for AIM have been decreasing by -11.26% on average. This is quite bad
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-188.89%
Revenue 1Y (TTM)44.29%
Revenue growth 3Y7.41%
Revenue growth 5Y-11.26%
Revenue growth Q2Q16.07%
3.2 Future
The Earnings Per Share is expected to grow by 24.23% on average over the next years. This is a very strong growth
Based on estimates for the next years, AIM will show a very strong growth in Revenue. The Revenue will grow by 217.99% on average per year.
EPS Next Y24.25%
EPS Next 2Y11.47%
EPS Next 3Y7.51%
EPS Next 5Y24.23%
Revenue Next Year-10.83%
Revenue Next 2Y304.62%
Revenue Next 3Y189.77%
Revenue Next 5Y217.99%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
AIM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AIM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.47%
EPS Next 3Y7.51%
5. Dividend
5.1 Amount
No dividends for AIM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AIM IMMUNOTECH INC
NYSEARCA:AIM (5/3/2024, 7:04:00 PM)
After market: 0.418 +0.01 (+3.26%)0.4048
+0 (+0.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap20.20M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -149.44% | ||
| ROE | -283% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.21% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.68 | ||
| Quick Ratio | 1.68 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y24.25%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)44.29%
Revenue growth 3Y7.41%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y